drugset

drugset / Trial / NCT02855346

PK and Safety Study of Vaginal Rings Containing Dapivirine and Levonorgestrel

NCT02855346 ↗

Phase 1 Completed 24 enrolled International Partnership for Microbicides, Inc. National Institutes of Health (NIH) · collab

RandomizedSingle-groupOpen-labelPrevention

Summary

PK and Safety Study of Vaginal Ring Containing Dapivirine and Levonorgestrel

Timeline

Start: 2017-05-03
Primary completion: 2017-08-18
Completion: 2017-08-18

Publications

Friedland BA, Gundacker H, Achilles SL, Chen BA, Hoesley C, Richardson BA, Kelly CW, Piper J, Johnson S, Devlin B, Steytler J, Kleinbeck K, Dangi B, Friend C, Song M, Mensch B, van der Straten A, Jacobson C, Hendrix CW, Brown J, Blithe D, Hiller SL; MTN-030/IPM 041 and MTN-044/IPM 053/CCN019 Protocol Teams for the Microbicide Trials Network and the Contraceptive Clinical Trials Network. Acceptability of a dapivirine levonorgestrel vaginal ring in two Phase 1 trials (MTN-030/IPM 041 and MTN-044/IPM 053/CCN019): Implications for multipurpose prevention technology development. PLoS One. 2025 Jan 14;20(1):e0312957. doi: 10.1371/journal.pone.0312957. eCollection 2025.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Levonorgestrel	Small molecule	320 mg	Other
Subject	dapivirine	Small molecule	200 mg	Other

Indications

No indication recorded.